Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma

European Urology, Supplements

Volumn 8, Issue 10, 2009, Pages 815-819

  Bracarda, Sergio ^a   Ravaud, Alain ^b,c   Chiodi, Marino ^d  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b HÔPITAL SAINT ANDRÉ   (France)

^c Centre of Clinical Investigation Clinical Epidemiology   (France)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Case reports; Everolimus; Metastatic renal cell carcinoma; Sequential therapy

Indexed keywords

CAPECITABINE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; SORAFENIB; SUNITINIB;

ADULT; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; KIDNEY CARCINOMA; KIDNEY METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMATITIS;

EID: 70349312352     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.08.007     Document Type: Review

References (15)

1. International Agency for Research on Cancer. GLOBOCAN database 2002. CANCERMondial Web site. http://www-dep.iarc.fr/. Accessed June 2009.
2. NCCN clinical practice guidelines in oncology: kidney cancer. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Updated 2009. Accessed June 2009.
3. Gupta K., Miller J.D., Li J.Z., Russell M.W., and Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34 (2008) 193-205
4. Athar U., and Gentile T.C. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 15 (2008) 3954-3966
5. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163 (2000) 408-417
6. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
7. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
8. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Guidelines on renal cell carcinoma. European Association of Urology Web site. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/RCC.pdf. Updated March 2009. Accessed June 2009.
9. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
10. Escudier B., Ravaud A., Oudard S., et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma [abstract 72]. Ann Oncol 19 (2008) viii45
11. Jac J., Amato R.J., Giessinger S., Saxena S., and Willis J.P. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. J Clin Oncol 26 (2008) abstract 5113
12. Amato R.J., Jac J., Giessinger S., Saxena S., and Willis J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115 (2009) 2438-2446
13. Bracarda S., and Ravaud A. Current and future treatment options for metastatic renal cell carcinoma. Eur Urol Suppl 8 (2009) 799-808
14. Ravaud A., and Wallerand H. Molecular pathways in metastatic renal cell carcinoma: the evolving role of mammalian target of rapamycin inhibitors. Eur Urol Suppl 8 (2009) 793-798
15. Patard J.-J. Treatment algorithms in metastatic renal cell carcinoma, including the potential role for the novel oral mammalian target of rapamycin inhibitor everolimus. Eur Urol Suppl 8 (2009) 809-814